Phase I Trial of AZD2171, an Orally Bioavailable Antiangiogenic Agent, in Pediatric Patients with Refractory

Study identifier:D8480C00016

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Phase I Trial of AZD2171, an Orally Bioavailable Antiangiogenic Agent, in Pediatric Patients with Refractory

Medical condition

Oncology

Phase

Phase 1

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jul 2007
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

-

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria